{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:44:11Z","timestamp":1780717451373,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T00:00:00Z","timestamp":1453334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astellas Pharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10147-016-0952-6","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T05:23:52Z","timestamp":1453353832000},"page":"773-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A multicenter phase I\/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer"],"prefix":"10.1007","volume":"21","author":[{"given":"Hideyuki","family":"Akaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,21]]},"reference":[{"key":"952_CR1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jjco\/hyh061","volume":"34","author":"H Akaza","year":"2004","unstructured":"Akaza H, Usami M, Hinotsu S et al (2004) Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 34:329\u2013336","journal-title":"Jpn J Clin Oncol"},{"key":"952_CR2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bju.12937","volume":"117","author":"MR Cooperberg","year":"2016","unstructured":"Cooperberg MR, Hinotsu S, Namiki M et al (2016) Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for prostate cancer. BJU Int 117:102\u2013109","journal-title":"BJU Int"},{"key":"952_CR3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jjco\/hym098","volume":"37","author":"S Hinotsu","year":"2007","unstructured":"Hinotsu S, Akaza H, Usami M et al (2007) Current status of endocrine therapy for prostate cancer in Japan\u2013\u2013analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 37:775\u2013781","journal-title":"Jpn J Clin Oncol"},{"key":"952_CR4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/jjco\/hyu104","volume":"44","author":"M Onozawa","year":"2014","unstructured":"Onozawa M, Hinotsu S, Tsukamoto T et al (2014) Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol 44:969\u2013981","journal-title":"Jpn J Clin Oncol"},{"key":"952_CR5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"952_CR6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12032-013-0717-2","volume":"30","author":"K Matsumoto","year":"2013","unstructured":"Matsumoto K, Tanaka N, Hayakawa N et al (2013) Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature. Med Oncol 30:717","journal-title":"Med Oncol"},{"key":"952_CR7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572\u2013583","journal-title":"Eur Urol"},{"key":"952_CR8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jjco\/hyn029","volume":"38","author":"S Naito","year":"2008","unstructured":"Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38:365\u2013372","journal-title":"Jpn J Clin Oncol"},{"key":"952_CR9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"952_CR10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS Bono de","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147\u20131154","journal-title":"Lancet"},{"key":"952_CR11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005","journal-title":"N Engl J Med"},{"key":"952_CR12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148","journal-title":"N Engl J Med"},{"key":"952_CR13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433","journal-title":"N Engl J Med"},{"key":"952_CR14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197","journal-title":"N Engl J Med"},{"key":"952_CR15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422","journal-title":"N Engl J Med"},{"key":"952_CR16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223","journal-title":"N Engl J Med"},{"key":"952_CR17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787\u2013790","journal-title":"Science"},{"key":"952_CR18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4155\/bio.13.325","volume":"6","author":"D Bennett","year":"2014","unstructured":"Bennett D, Gibbons JA, Mol R et al (2014) Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS\/MS. Bioanalysis 6:737\u2013744","journal-title":"Bioanalysis"},{"key":"952_CR19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet 375:1437\u20131446","journal-title":"Lancet"},{"key":"952_CR20","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.24395","volume":"115","author":"H Akaza","year":"2009","unstructured":"Akaza H, Hinotsu S, Usami M et al (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115:3437\u20133445","journal-title":"Cancer"},{"key":"952_CR21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.eururo.2014.10.004","volume":"67","author":"R Venkitaraman","year":"2015","unstructured":"Venkitaraman R, Lorente D, Murthy V et al (2015) A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67:673\u2013679","journal-title":"Eur Urol"},{"key":"952_CR22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jjco\/hyt230","volume":"44","author":"N Kamiya","year":"2014","unstructured":"Kamiya N, Suzuki H, Nishimura K et al (2014) Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. Jpn J Clin Oncol 44:263\u2013269","journal-title":"Jpn J Clin Oncol"},{"key":"952_CR23","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","volume":"28","author":"CJ Ryan","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481\u20131488","journal-title":"J Clin Oncol"},{"key":"952_CR24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cncr.28518","volume":"120","author":"S Badrising","year":"2014","unstructured":"Badrising S, van der Noort V, van Oort IM et al (2014) Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120:968\u2013975","journal-title":"Cancer"},{"key":"952_CR25","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","volume":"24","author":"Y Loriot","year":"2013","unstructured":"Loriot Y, Bianchini D, Ileana E et al (2013) Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24:1807\u20131812","journal-title":"Ann Oncol"},{"key":"952_CR26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028\u20131038","journal-title":"N Engl J Med"},{"key":"952_CR27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","volume":"23","author":"DF Gleason","year":"1992","unstructured":"Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23:273\u2013279","journal-title":"Hum Pathol"},{"key":"952_CR28","volume-title":"International Union Against Cancer (UICC): TNM classification of malignant tumors","author":"LH Sobin","year":"2002","unstructured":"Sobin LH, Wittekind C (2002) International Union Against Cancer (UICC): TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York","edition":"6"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-016-0952-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-016-0952-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-016-0952-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:07:51Z","timestamp":1553612871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-016-0952-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,21]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1007\/s10147-016-0952-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,21]]}}}